MannKind Corporation (NASDAQ:MNKD) Given Average Recommendation of “Moderate Buy” by Analysts

MannKind Corporation (NASDAQ:MNKD) has received a consensus recommendation of “Moderate Buy” from the nine ratings firms that are covering the company, Marketbeat reports. Three research analysts have rated the stock with a hold recommendation, five have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $9.2143.

A number of equities analysts have weighed in on MNKD shares. Wall Street Zen lowered shares of MannKind from a “buy” rating to a “hold” rating in a report on Saturday. Weiss Ratings reissued a “hold (c)” rating on shares of MannKind in a research report on Thursday, January 22nd. Zacks Research downgraded MannKind from a “strong-buy” rating to a “hold” rating in a report on Tuesday, February 10th. Royal Bank Of Canada reiterated a “sector perform” rating and set a $3.50 target price (down from $7.50) on shares of MannKind in a report on Friday. Finally, Truist Financial set a $9.00 price target on shares of MannKind in a report on Monday, November 24th.

MannKind News Roundup

Here are the key news stories impacting MannKind this week:

• Positive Sentiment: Revenue beat and growth outlook — MannKind reported Q4 revenue of about $112M (+46% YoY) and management outlined a roughly $450M 2026 revenue run‑rate while preparing an Afrezza pediatric launch, which supports longer‑term upside. MannKind Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
• Positive Sentiment: Analyst keeps “overweight” despite cut — Wells Fargo trimmed its price target from $8 to $7 but maintained an overweight rating, signaling continued analyst conviction in upside even after the EPS miss. Wells Fargo price target note
• Neutral Sentiment: Heavy options activity — Reports show large volume of call option purchases in MNKD, which can amplify intraday moves and reflects some speculative bullish positioning but is not a guarantee of sustained upside. Investors Purchase Large Volume of MannKind Call Options
• Neutral Sentiment: Mixed metric readouts — Analysts note revenue comfortably beat estimates while EPS missed (-$0.05 vs. -$0.01 expected), leaving valuation/forward EPS expectations in flux—important context but mixed for immediate direction. MannKind Reports Q4 Loss, Tops Revenue Estimates
• Negative Sentiment: EPS miss and unexpected quarterly loss drove the sell‑off — The bottom‑line shortfall led to a sharp intraday drop and a 52‑week low as investors reacted negatively to the EPS miss despite revenue growth. Why MannKind Stock Tumbled on Thursday
• Negative Sentiment: RBC cut price target sharply — Royal Bank of Canada cut its target from $7.50 to $3.50 (sector perform), reducing near‑term analyst support and adding selling pressure. RBC rating/price target note
• Negative Sentiment: Broader biotech weakness — A sector‑wide pullback (“biotech bloodbath”) this week has dragged MNKD along with peers, amplifying downside from company‑specific negatives. Biotech Bloodbath Drags Health Care Down as MannKind and Soleno Stocks Sink
• Negative Sentiment: Competitive risk flagged — News that United Therapeutics is considering a new treprostinil formulation pressured MannKind (and peers), introducing potential product/market risk for inhaled/treprostinil formulations. United Therapeutics mulls new treprostinil formulation

Insider Buying and Selling at MannKind

In other MannKind news, insider Stuart A. Tross sold 47,006 shares of the company’s stock in a transaction that occurred on Thursday, January 8th. The stock was sold at an average price of $6.33, for a total value of $297,547.98. Following the completion of the transaction, the insider owned 985,007 shares in the company, valued at $6,235,094.31. This represents a 4.55% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Michael Castagna sold 65,804 shares of the company’s stock in a transaction on Wednesday, December 17th. The shares were sold at an average price of $6.01, for a total transaction of $395,482.04. Following the completion of the transaction, the chief executive officer owned 2,504,792 shares of the company’s stock, valued at $15,053,799.92. This trade represents a 2.56% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 262,846 shares of company stock valued at $1,546,840. 2.70% of the stock is owned by insiders.

Institutional Investors Weigh In On MannKind

A number of institutional investors have recently modified their holdings of the stock. Rubric Capital Management LP bought a new position in MannKind during the third quarter worth $61,297,000. Frazier Life Sciences Management L.P. bought a new stake in MannKind during the fourth quarter valued at $23,956,000. State Street Corp raised its holdings in shares of MannKind by 36.2% during the fourth quarter. State Street Corp now owns 14,623,269 shares of the biopharmaceutical company’s stock worth $82,914,000 after purchasing an additional 3,883,071 shares during the period. UBS Group AG lifted its position in shares of MannKind by 146.7% in the 3rd quarter. UBS Group AG now owns 5,194,739 shares of the biopharmaceutical company’s stock worth $27,896,000 after buying an additional 3,088,820 shares during the last quarter. Finally, Wellington Management Group LLP boosted its holdings in shares of MannKind by 316.2% in the 3rd quarter. Wellington Management Group LLP now owns 3,467,721 shares of the biopharmaceutical company’s stock valued at $18,622,000 after buying an additional 2,634,533 shares during the period. Institutional investors and hedge funds own 49.55% of the company’s stock.

MannKind Price Performance

Shares of NASDAQ MNKD opened at $3.28 on Friday. The firm’s 50-day moving average is $5.55 and its two-hundred day moving average is $5.36. The company has a market capitalization of $1.01 billion, a PE ratio of 164.08 and a beta of 0.84. MannKind has a 12-month low of $2.93 and a 12-month high of $6.51.

MannKind (NASDAQ:MNKD) last posted its earnings results on Thursday, February 26th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.04). MannKind had a net margin of 1.68% and a negative return on equity of 11.12%. The company had revenue of $111.96 million during the quarter, compared to analysts’ expectations of $99.85 million. During the same period in the previous year, the company posted $0.03 EPS. MannKind’s quarterly revenue was up 45.8% compared to the same quarter last year. On average, analysts forecast that MannKind will post 0.1 EPS for the current fiscal year.

MannKind Company Profile

MannKind Corporation is a biopharmaceutical company specialized in the development and commercialization of inhaled therapeutic products. The company’s core business revolves around its proprietary Technosphere® drug‐delivery platform, which is designed to enable rapid absorption of small‐molecule drugs through pulmonary administration. MannKind’s lead product, Afrezza®, is an inhaled insulin therapy intended for adults with type 1 and type 2 diabetes, offering users a rapid‐acting alternative to traditional injectable insulins.

Afrezza received U.S.